Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Comorbid Allergic Rhinitis

Main Article Content

Jonathan Spergel
Children?s Hospital of Philadelphia and Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, USA

Michael Blaiss
Medical College of Georgia at Augusta University, Augusta, GA, USA

Peter Lio
Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Chicago Integrative Eczema Center, Chicago, IL, USA

Aharon Kessel
Bnai Zion Medical Center, Haifa, Israel; Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel

Liza Takiya
Pfizer Inc., Collegeville, PA, USA

John Werth
Pfizer Inc., Collegeville, PA, USA

Michael O'Connell
Pfizer Inc., Collegeville, PA, USA

Chuanbo Zang
Pfizer Inc., Collegeville, PA, USA

Michael Cork
Sheffield Dermatology Research, IICD, University of Sheffield, Sheffield Children?s Hospital, Sheffield, United Kingdom

Keywords

Atopic Dermatitis, Allergic Rhinitis, Crisaborole, Efficacy, Safety

Abstract

Abstract not available.

References

1. Dharmage SC et al. Allergy. 2014;69:17-27.

2. Silverberg JI. Ann Allergy Asthma Immunol. 2019;123:144-151.

3. Silverberg JI. Clin Dermatol. 2017;35:360-366.

4. Eucrisa (crisaborole) ointment, 2%, for topical use [package insert]. New York, NY: Pfizer Labs; April 2020.

5. Paller AS et al. J Am Acad Dermatol. 2016;75:494-503.e496.

6. Hanifin JM, Rajka G. Acta Derm Venereol. 1980;60:44-47.

7. Yosipovitch G et al. Itch. 2018;3:e13.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.13

Article Details

How to Cite
[1]
Spergel, J., Blaiss, M., Lio, P., Kessel, A., Takiya, L., Werth, J., O’Connell, M., Zang, C. and Cork, M. 2021. Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Comorbid Allergic Rhinitis. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s13. DOI:https://doi.org/10.25251/skin.5.supp.13.
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 > >>